Cargando…
Hormonal treatments for endometriosis: The endocrine background
Endometriosis is a benign uterine disorder characterized by menstrual pain and infertility, deeply affecting women’s health. It is a chronic disease and requires a long term management. Hormonal drugs are currently the most used for the medical treatment and are based on the endocrine pathogenetic a...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9156507/ https://www.ncbi.nlm.nih.gov/pubmed/34405378 http://dx.doi.org/10.1007/s11154-021-09666-w |
_version_ | 1784718466425552896 |
---|---|
author | Vannuccini, Silvia Clemenza, Sara Rossi, Margherita Petraglia, Felice |
author_facet | Vannuccini, Silvia Clemenza, Sara Rossi, Margherita Petraglia, Felice |
author_sort | Vannuccini, Silvia |
collection | PubMed |
description | Endometriosis is a benign uterine disorder characterized by menstrual pain and infertility, deeply affecting women’s health. It is a chronic disease and requires a long term management. Hormonal drugs are currently the most used for the medical treatment and are based on the endocrine pathogenetic aspects. Estrogen-dependency and progesterone-resistance are the key events which cause the ectopic implantation of endometrial cells, decreasing apoptosis and increasing oxidative stress, inflammation and neuroangiogenesis. Endometriotic cells express AMH, TGF-related growth factors (inhibin, activin, follistatin) CRH and stress related peptides. Endocrine and inflammatory changes explain pain and infertility, and the systemic comorbidities described in these patients, such as autoimmune (thyroiditis, arthritis, allergies), inflammatory (gastrointestinal/urinary diseases) and mental health disorders. The hormonal treatment of endometriosis aims to block of menstruation through an inhibition of hypothalamus-pituitary-ovary axis or by causing a pseudodecidualization with consequent amenorrhea, impairing the progression of endometriotic implants. GnRH agonists and antagonists are effective on endometriosis by acting on pituitary-ovarian function. Progestins are mostly used for long term treatments (dienogest, NETA, MPA) and act on multiple sites of action. Combined oral contraceptives are also used for reducing endometriosis symptoms by inhibiting ovarian function. Clinical trials are currently going on selective progesterone receptor modulators, selective estrogen receptor modulators and aromatase inhibitors. Nowadays, all these hormonal drugs are considered the first-line treatment for women with endometriosis to improve their symptoms, to postpone surgery or to prevent post-surgical disease recurrence. This review aims to provide a comprehensive state-of-the-art on the current and future hormonal treatments for endometriosis, exploring the endocrine background of the disease. |
format | Online Article Text |
id | pubmed-9156507 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-91565072022-06-02 Hormonal treatments for endometriosis: The endocrine background Vannuccini, Silvia Clemenza, Sara Rossi, Margherita Petraglia, Felice Rev Endocr Metab Disord Article Endometriosis is a benign uterine disorder characterized by menstrual pain and infertility, deeply affecting women’s health. It is a chronic disease and requires a long term management. Hormonal drugs are currently the most used for the medical treatment and are based on the endocrine pathogenetic aspects. Estrogen-dependency and progesterone-resistance are the key events which cause the ectopic implantation of endometrial cells, decreasing apoptosis and increasing oxidative stress, inflammation and neuroangiogenesis. Endometriotic cells express AMH, TGF-related growth factors (inhibin, activin, follistatin) CRH and stress related peptides. Endocrine and inflammatory changes explain pain and infertility, and the systemic comorbidities described in these patients, such as autoimmune (thyroiditis, arthritis, allergies), inflammatory (gastrointestinal/urinary diseases) and mental health disorders. The hormonal treatment of endometriosis aims to block of menstruation through an inhibition of hypothalamus-pituitary-ovary axis or by causing a pseudodecidualization with consequent amenorrhea, impairing the progression of endometriotic implants. GnRH agonists and antagonists are effective on endometriosis by acting on pituitary-ovarian function. Progestins are mostly used for long term treatments (dienogest, NETA, MPA) and act on multiple sites of action. Combined oral contraceptives are also used for reducing endometriosis symptoms by inhibiting ovarian function. Clinical trials are currently going on selective progesterone receptor modulators, selective estrogen receptor modulators and aromatase inhibitors. Nowadays, all these hormonal drugs are considered the first-line treatment for women with endometriosis to improve their symptoms, to postpone surgery or to prevent post-surgical disease recurrence. This review aims to provide a comprehensive state-of-the-art on the current and future hormonal treatments for endometriosis, exploring the endocrine background of the disease. Springer US 2021-08-17 2022 /pmc/articles/PMC9156507/ /pubmed/34405378 http://dx.doi.org/10.1007/s11154-021-09666-w Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Vannuccini, Silvia Clemenza, Sara Rossi, Margherita Petraglia, Felice Hormonal treatments for endometriosis: The endocrine background |
title | Hormonal treatments for endometriosis: The endocrine background |
title_full | Hormonal treatments for endometriosis: The endocrine background |
title_fullStr | Hormonal treatments for endometriosis: The endocrine background |
title_full_unstemmed | Hormonal treatments for endometriosis: The endocrine background |
title_short | Hormonal treatments for endometriosis: The endocrine background |
title_sort | hormonal treatments for endometriosis: the endocrine background |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9156507/ https://www.ncbi.nlm.nih.gov/pubmed/34405378 http://dx.doi.org/10.1007/s11154-021-09666-w |
work_keys_str_mv | AT vannuccinisilvia hormonaltreatmentsforendometriosistheendocrinebackground AT clemenzasara hormonaltreatmentsforendometriosistheendocrinebackground AT rossimargherita hormonaltreatmentsforendometriosistheendocrinebackground AT petragliafelice hormonaltreatmentsforendometriosistheendocrinebackground |